AstraZeneca PLC (NASDAQ:AZN)
| 68.61 BATS BZX Real-Time Price As of 1:15pm ET |  +0.01 / +0.01%Today’s Change | 52.65 Today|||52-Week Range 72.12 | +1.19% Year-to-Date |
Latest AZN News | Press Releases
| Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study Mar 27 / Zacks.com - Paid Partner Content | Here's What is Driving Amgen (AMGN) Stock's Outperformance Mar 22 / Zacks.com - Paid Partner Content |
| Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7% Mar 24 / Zacks.com - Paid Partner Content | Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023? Mar 20 / Zacks.com - Paid Partner Content |
| Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know Mar 23 / Zacks.com - Paid Partner Content | Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know Mar 17 / Zacks.com - Paid Partner Content |
| How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings Mar 23 / Zacks.com - Paid Partner Content | 2 Steady Stocks to Buy and Hold Forever Mar 17 / MotleyFool.com - Paid Partner Content |
| 3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030 Mar 23 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 68.60 |
| Today’s open | 68.84 |
| Day’s range | 68.38 - 68.86 |
| Volume | 192,739 |
| Average volume (3 months) | 4,758,027 |
| Market cap | $210.5B |
Data as of 1:15pm ET, 03/29/2023
Growth & Valuation
| Earnings growth (last year) | +2,588.61% |
| Earnings growth (this year) | +8.78% |
| Earnings growth (next 5 years) | +14.88% |
| Revenue growth (last year) | +17.23% |
| P/E ratio | 65.0 |
| Price/Sales | 4.77 |
| Price/Book | 5.68 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | +0.18 | +0.45% |
| NVSNovartis | -0.85 | -0.93% |
| NVONovo Nordisk | +1.12 | +0.72% |
| MRKMerck | -0.55 | -0.52% |
Data as of 1:16pm ET, 03/29/2023
Financials
| Next reporting date | April 28, 2023 |
| EPS forecast (this quarter) | $0.87 |
| Annual revenue (last year) | $44.4B |
| Annual profit (last year) | $3.3B |
| Net profit margin | 7.41% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Cambridgeshire |
Forecasts
